DE-122 (carotuximab) is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. DE-122 was licensed to Santen Pharmaceutical Co., Ltd., who is studying DE-122 in the randomized Phase 2 AVANTE trial for patients with wet AMD, the leading cause of blindness in the western world.